PropertyValue
?:abstract
  • Increase in thrombotic and microvascular complications is emerging to be a key feature of patients with critical illness associated with COVID-19 infection. While endotheliopathy is thought to be a key factor of COVID-19-associated coagulopathy, markers indicative of this process that are prognostic of disease severity have not been well-established in this patient population. Using plasma profiling of patients with COVID-19, we identified circulating markers that segregated with disease severity: markers of angiogenesis (VEGF-A, PDGF-AA and PDGF-AB/BB) were elevated in hospitalized patients with non-critical COVID-19 infection, while markers of endothelial injury (angiopoietin-2, FLT-3L, PAI-1) were elevated in patients with critical COVID-19 infection. In survival analysis, elevated markers of endothelial injury (angiopoietin-2, follistatin, PAI-1) were strongly predictive of in-hospital mortality. Our findings demonstrate that non-critical and critical phases of COVID-19 disease may be driven by distinct mechanisms involving key aspects of endothelial cell function, and identify drivers of COVID-19 pathogenesis and potential targets for future therapies.
is ?:annotates of
?:creator
?:doi
  • 10.1177/2045894020966547
?:doi
?:journal
  • Pulm_Circ
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/6dc4362b33eef5b76c6749012c8d10527a062186.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7691906.xml.json
?:pmcid
?:pmid
?:pmid
  • 33282193.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Circulating markers of angiogenesis and endotheliopathy in COVID-19
?:type
?:year
  • 2020-11-25

Metadata

Anon_0  
expand all